Market Overview

The Global Epilepsy Drugs Market was valued at USD 11,307.0 million in 2023 and is expected to reach USD 17,352.6 million by 2031 while growing at a CAGR of 5.5% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global epilepsy drugs market growth. Epilepsy drugs, referred to as antiepileptic drugs (AEDs) or anticonvulsants, are medications utilized in the management and treatment of epilepsy, a neurological disorder featuring recurrent seizures. They function by diminishing excessive brain electrical activity triggering seizures or by stabilizing the neuronal membrane to avert abnormal electrical impulses.

The increasing prevalence of epilepsy, coupled with ongoing research and development efforts resulting in the discovery of new antiepileptic drugs with improved efficacy, tolerability, and safety profiles, drives the epilepsy drugs market. Nevertheless, side effects and safety concerns, along with drug resistance, impede the growth of the market.

Furthermore, the global epilepsy drugs industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Product Analysis

The Global Epilepsy Drugs Market is segmented among First Generation Anti-epileptics, Second Generation Anti-epileptics, and Third Generation Anti-epileptics, based on Product. In 2023, First Generation Anti-epileptics accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Epilepsy Drugs Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Novartis AG, GlaxoSmithKline plc, Sanofi, UCB S.A., Abbott Laboratories, Bausch Health Companies, Inc, Viatris Inc., Johnson & Johnson, Sumitomo Pharma Co., Ltd, and H. Lundbeck A/S.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Epilepsy Drugs Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Epilepsy Drugs Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Epilepsy Drugs Market Segmentation, By Product

• Global Epilepsy Drugs Market Share Analysis, By Product

• Global Epilepsy Drugs Market Growth Analysis, By Product

• Global Epilepsy Drugs Market Trends, By Product

o First Generation Anti-epileptics

o Second Generation Anti-epileptics

o Third Generation Anti-epileptics

6. Global Epilepsy Drugs Market Segmentation, By Region

• Global Epilepsy Drugs Market Share Analysis, By Region

• Global Epilepsy Drugs Market Growth Analysis, By Region

• Global Epilepsy Drugs Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

7. Competitive Landscape

• Novartis AG*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• GlaxoSmithKline plc

• Sanofi, UCB S.A.

• Abbott Laboratories

• Bausch Health Companies, Inc

• Viatris Inc.

• Johnson & Johnson

• Sumitomo Pharma Co., Ltd

• H. Lundbeck A/S.  

*Similar analysis will be provided for each company listed above.